Home > Healthcare & Medical Devices > Mechanical Thrombectomy Devices Market
Mechanical Thrombectomy Devices Market Size is anticipated to witness significant growth from 2023 to 2032 on account of the expanding geriatric population and an acceleration in the rate of cardiovascular diseases worldwide. Various factors like hectic schedules, physical inactivity, and unhealthy diet, along with harmful intake of alcohol and use of tobacco, will also aid market progression.
Mechanical thrombectomy is a minimally invasive procedure to remove blood clots from veins and arteries, which can cause intrusion in the normal flow of blood leading to life-threatening conditions like strokes. The procedure uses various techniques like stent-retrieval, and catheter-based therapies to unclog arteries.
The rise in the use of clot retrievers and stents to treat strokes and an upsurge in the number of vascular diseases is set to drive the use of thrombectomy in surgical centers and hospitals. Additionally, the rising investment in research and development activities to bring in top-notch thrombectomy devices by manufacturers will also propel the demand of the global mechanical thrombectomy device market.
The mechanical thrombectomy devices market from the automated device segment is poised to increase significantly by 2032 owing to the proliferation of automation technology in the healthcare sector. An automated system reduces labor costs and delivers precise, accurate outcomes of higher quality. Automated thrombectomy devices employ a variety of control systems that remove blood vessel clots automatically. These devices include thrombectomy tools, which function consecutively under computer control. Thus, the numerous benefits of automated devices are expected to drive market expansion.
Based on end-user, the mechanical thrombectomy devices industry from the hospitals segment is slated to register notable progress by 2032 backed by surging product usage for the treatment of acute ischemic stroke patients with large artery diseases using stent retrievers in these settings. With the technological developments in minimally invasive surgeries, the use of new thrombectomy devices, endovascular thrombectomy with catheters and stent retrievers, and interventional therapy have emerged as the standard treatment for chronic diseases. Due to the non-invasive treatment technology, the patient can be treated within 24 hours in certain cases, which makes it a highly effective method for removing clots. The increase in the number of hospitals across the globe will complement segment outlook.
Regionally, the North America mechanical thrombectomy devices market will observe considerable rise by 2032 owing to the ongoing technological advancements, cost-effective treatment, increase in the geriatric population, and rising number of patients suffering from neurological and cardiovascular diseases in the region. According to the National Institute of Health, heart ailments like strokes are the most common reason for fatalities in the United States. The increase in the adoption of mechanical thrombectomy treatments as well as medical reimbursement services from various central governments will augment the regional market revenues by 2032.
The prominent players operating in the mechanical thrombectomy devices market are Edward Lifesciences Corporation, Stryker Corporation, Boston Scientific, Johnson & Johnson, Argon Medical Devices Inc., and others.